KalVista Pharmaceuticals Investor Relations Material

KalVista Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecule protease inhibitors, which are primarily aimed at treating diseases with significant unmet medical needs. The company focuses on advancing a portfolio of inhibitors targeting the kallikrein-kinin system, a key pathway in the human body related to swelling and inflammation. KalVista's research has produced sebetralstat, an oral treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition characterized by spontaneous episodes of swelling. Additionally, the company is exploring oral Factor XIIa inhibitors, which are in preclinical development stages, for the prophylactic treatment of HAE, along with potential therapies for thrombosis and inflammation. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.